Danish biotech company Zealand Pharma A/S ZLDPF has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial of its weight management drug, petrelintide. The trial results were released on Thursday and comes at a time when the weightloss drug market is experiencing domination of another Danish pharmaceutical company Novo Nordisk NVO NONOF which produces Ozempic and WeGovy.
What Happened: As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of petrelintide. The drug, designed for weight management, demonstrated “significant and clinically meaningful reductions in body weight with a very favorable tolerability profile,” stated David Kendall, MD, Chief Medical Officer of Zealand Pharma.
The study involved 48 participants, predominantly male, who received 16 weekly doses of either petrelintide or a placebo. The average body weight decreased by 8.6% among participants who completed treatment with high dose petrelintide, compared to a 1.7% decrease in the placebo group.
Petrelintide was well received, with no serious or severe adverse events reported. Zealand Pharma plans to initiate a Phase 2b clinical trial of petrelintide later in 2024.
See Also: Medicare Agency To End Advance Payments Following UnitedHealth Cyberattack
Why It Matters: The global market for weight-loss drugs is projected to reach a staggering $150 billion by the early 2030s, a significant leap from the previous forecast of $100 billion. This surge is attributed to the growing availability of weight-loss medications from companies like Novo Nordisk and Eli Lilly and Co LLY.
Novo Nordisk, the maker of Ozempic, is reportedly set to overtake Denmark's iconic toymaker, Lego A/S, as the nation's most valuable brand, thanks to the surging popularity of its weight-loss drugs on a global scale.
Price Action: Following the news, Zealand stocks closed about 10% higher at $100 on the OTC, according to Benzinga Pro.
Image via Midjourney
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
